ArticleFrontiers in pharmacology2026
Protective effects of a commercial total flavonoid preparation from
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study investigated the protective effects of a commercial total flavonoid preparation derived from Methods: A mouse model of exhaustive exercise-induced liver injury was established by exhaustive swimming. Mice were assigned to a normal control group, an exercise model group, a silymarin-treated group, and low-, medium-, and high-dose total flavonoid preparation groups. Liver function, histopathological alterations, oxidative stress-related parameters, inflammatory mediators, and NF-κB-related signaling proteins were evaluated after 4 weeks of treatment. Results: Exhaustive exercise induced marked liver injury, as evidenced by elevated serum ALT and AST levels, histopathological damage, aggravated oxidative stress, and increased inflammatory responses. In the exercise model group, serum GSH decreased from 155.77 ± 9.32 to 71.64 ± 4.20 μmol/L, hepatic MDA increased from 3.80 ± 1.50 to 8.34 ± 1.58 nmol/mg protein, hepatic GSH decreased from 1.43 ± 0.05 to 1.00 ± 0.07 nmol/mg protein, and hepatic SOD decreased from 0.92 ± 0.56 to 0.33 ± 0.21 U/mg protein. Treatment with the tested total flavonoid preparation attenuated these alterations, with the medium-dose group showing the most consistent effects, including restoration of serum GSH to 135.84 ± 10.49 μmol/L, reduction of hepatic MDA to 4.07 ± 0.68 nmol/mg protein, increase of hepatic GSH to 1.35 ± 0.05 nmol/mg protein, and increase of hepatic SOD to 0.86 ± 0.07 U/mg protein. The preparation also reduced inflammatory mediator expression and modulated NF-κB-related signaling, as reflected by decreased p-IKKα and increased p-IκBα expression. Conclusion: The tested total flavonoid preparation attenuated exhaustive exercise-induced liver injury in mice. Its protective effects were associated with reduced oxidative stress, suppression of inflammatory responses, and modulation of NF-κB-related signaling, supporting its potential value in preventing exercise-related hepatic stress.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.